Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

BACKGROUND: ChAdOx1-vectored vaccine candidates against several pathogens have been developed and tested in clinical trials and ChAdOx1 nCoV-19 has now been licensed for emergency use for COVID-19. We assessed the safety and immunogenicity of the ChAdOx1 MERS vaccine in a phase 1b trial in healthy M...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosaeed, Mohammad, Balkhy, Hanan H, Almaziad, Sultan, Aljami, Haya A, Alhatmi, Hind, Alanazi, Hala, Alahmadi, Mashael, Jawhary, Ayah, Alenazi, Mohammed W, Almasoud, Abdulrahman, Alanazi, Rawan, Bittaye, Mustapha, Aboagye, Jeremy, Albaalharith, Nahla, Batawi, Sarah, Folegatti, Pedro, Ramos Lopez, Fernando, Ewer, Katie, Almoaikel, Khalid, Aljeraisy, Majed, Alothman, Adel, Gilbert, Sarah C, Khalaf Alharbi, Naif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565931/
https://www.ncbi.nlm.nih.gov/pubmed/34751259
http://dx.doi.org/10.1016/S2666-5247(21)00193-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565931/
https://www.ncbi.nlm.nih.gov/pubmed/34751259
http://dx.doi.org/10.1016/S2666-5247(21)00193-2

Ejemplares similares